Microbiome Diagnostics for Cardiovascular Disease via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for characterizing cardiovascular disease conditions and providing tailored therapies based on microbiome analysis are limited due to technological constraints, leaving many questions unanswered and lacking viable solutions for individualized and population-wide diagnostics and therapeutics.
Innovation Solution
A method and system for characterizing cardiovascular disease conditions through microbiome-derived diagnostics and therapeutics, involving the receipt of biological samples, characterization of microbiome composition and functional features, and transformation into models for diagnosis and therapy recommendations, utilizing techniques such as deep sequencing and machine learning to predict disease states and provide personalized therapeutic measures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current sample processing and genetic analysis techniques are used for microbiome characterization, then the process is simpler and more resource-efficient, but the measurement precision and completeness of microbiome data are insufficient
Solution Approach 1:
The patent segments the microbiome characterization process into distinct phases: sample collection, DNA extraction, library preparation, sequencing, and data analysis. Each phase uses specialized techniques optimized for its specific function, allowing high precision through modular complexity rather than monolithic complexity.
Solution Approach 2:
The patent introduces intermediary steps and materials such as DNA extraction buffers, library preparation kits, and bioinformatics pipelines that mediate between the raw biological sample and the final characterization data. These intermediaries enable precise measurement by transforming complex biological information into analyzable data formats.
2Loss of information
If comprehensive microbiome analysis is performed to answer all health-related questions, then the diagnostic value and therapeutic insights are maximized, but the loss of time and resources for processing large amounts of data increases significantly
Solution Approach 1:
The patent performs preliminary actions by establishing reference databases of microbiome compositions associated with various health conditions before actual diagnostic analysis. During patient testing, the system compares individual microbiome data against these pre-established references, enabling rapid interpretation without requiring de novo analysis of all possible health parameters.
Solution Approach 2:
The patent extracts only the most relevant microbiome features and taxa that are associated with cardiovascular health from the complete microbiome dataset. This selective extraction focuses computational resources on diagnostically significant information while discarding redundant data, thereby reducing processing time without sacrificing essential diagnostic value.
3Adaptability or versatility
If microbiome-based diagnostics and therapeutics are developed for cardiovascular disease, then individualized and population-wide characterization becomes possible, but the ease of operation and clinical implementation becomes more difficult
Solution Approach 1:
The patent develops a universal microbiome characterization platform that can simultaneously serve individualized patient diagnostics and population-wide epidemiological studies. The same core technology pipeline processes both single-patient samples and aggregated population data, eliminating the need for separate systems and simplifying clinical implementation while maintaining adaptability to different study designs.
Data Source
AI summary
A method for at least one of characterizing, diagnosing, and treating a cardiovascular disease condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the cardiovascular disease condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the cardiovascular disease condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.